Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현 | - |
dc.date.accessioned | 2019-12-07T17:58:40Z | - |
dc.date.available | 2019-12-07T17:58:40Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.citation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v. 62, no. 7, Article no. e00011-18 | en_US |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.issn | 1098-6596 | - |
dc.identifier.uri | https://aac.asm.org/content/62/7/e00011-18 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/118248 | - |
dc.description.abstract | Although guidelines recommend amikacin (AMK) inhalation therapy for difficult-to-treat nontuberculous mycobacterial lung disease (NTM-LD), data are limited regarding the safety and clinical efficacy of this salvage therapy. We retrospectively evaluated the treatment outcomes of 77 patients with refractory NTM-LD caused by Mycobacterium abscessus complex (MABC) or M. avium complex (MAC) who initiated AMK inhalation therapy between February 2015 and June 2016. MABC was the most common etiology (n = 48, 62%), followed by MAC (n = 20, 26%) and mixed infections (n = 9, 12%). Isolates with macrolide resistance and baseline AMK resistance were identified in 63 (82%) patients and 5 (6%) patients, respectively. At 12 months after AMK inhalation therapy, 49% of patients had symptomatic improvement, whereas 42% had radiological improvement. Conversion to a negative sputum culture occurred in 14 (18%) patients, and the culture conversion rate was higher in patients infected with macrolide-susceptible isolates (7/14, 50%) than in those infected with macrolide-resistant isolates (7/63, 11%) (P = 0.003). Significant decreases in sputum semiquantitative culture positivity occurred after AMK inhalation therapy (P < 0.001). On multivariate analysis, conversion to a negative sputum culture was associated with mixed infections (P = 0.009), a forced expiratory volume in 1 s of greater than 60% (P = 0.008), and the absence of macrolide resistance (P = 0.003). Thirty-eight percent of patients experienced adverse effects, with ototoxicity (n = 15) being the most common. AMK inhalation salvage therapy may improve the treatment responses in some patients with refractory NTM-LD. However, considering the common adverse effects, further evaluation of the optimal dosage and intervals for AMK inhalation therapy is needed. | en_US |
dc.description.sponsorship | This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A2A1A01003959). Additional support was provided by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2778). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | AMER SOC MICROBIOLOGY | en_US |
dc.subject | nontuberculous mycobacteria | en_US |
dc.subject | Mycobacterium avium complex | en_US |
dc.subject | Mycobacterium abscessus | en_US |
dc.subject | amikacin | en_US |
dc.subject | inhalation | en_US |
dc.title | Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease | en_US |
dc.type | Article | en_US |
dc.relation.no | 7 | - |
dc.relation.volume | 62 | - |
dc.identifier.doi | 10.1128/AAC.00011-18 | - |
dc.relation.page | 11-18 | - |
dc.relation.journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.contributor.googleauthor | Jhun, Byung Woo | - |
dc.contributor.googleauthor | Yang, Bumhee | - |
dc.contributor.googleauthor | Moon, Seong Mi | - |
dc.contributor.googleauthor | Lee, Hyun | - |
dc.contributor.googleauthor | Park, Hye Yun | - |
dc.contributor.googleauthor | Jeon, Kyeongman | - |
dc.contributor.googleauthor | Kwon, O. Jung | - |
dc.contributor.googleauthor | Ahn, Jungmin | - |
dc.contributor.googleauthor | Moon, Il Joon | - |
dc.contributor.googleauthor | Shin, Sung Jae | - |
dc.relation.code | 2018002261 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | namuhanayeyo | - |
dc.identifier.researcherID | G-1336-2018 | - |
dc.identifier.orcid | http://orcid.org/0000-0002-1269-0913 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.